Mr. Juan Enriquez is an experienced business leader, author, and academic recognized as one of the world’s leading authorities on the economic and political impacts of life sciences. He is currently a Managing Director at Excel Venture Management, a life sciences and healthcare venture capital firm. Juan was the founding director of Harvard Business School’s Life Sciences Project and then founded Biotechonomy LLC, a life sciences research and investment firm. He has been an active investor in early-stage private companies in the biotechnology and information sciences sectors. While at Harvard, Juan wrote various articles and case studies, won a McKinsey Prize, and published the best-selling book As the Future Catches You, an analysis of the impact of genomics on business and society. His latest book, the Untied States of America, explores why, as technology advances, some countries are successful while others disappear. Juan serves on a number of boards including Cabot Corporation and The Harvard Medical School Genetics Advisory Council. He earned a BA and MBA from Harvard, with Honors.

Dr. Fetzer joined from SGI from Cerulean Pharma Inc., a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics, where he was President and CEO for five years. Under Dr. Fetzer’s leadership, Cerulean advanced from a pre-clinical platform company to become a publicly traded clinical development stage company with a pipeline of product candidates. Prior to Cerulean Pharma, Dr. Fetzer served in a variety of positions at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Research & Development, Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Business Development. Dr. Fetzer began his career in 1993 in various positions of increasing responsibility at the Boston Consulting Group (BCG), a global leading management consulting firm, including Consultant, Project Leader, Principal, Partner and Managing Director.

Dr. Fetzer served on the boards of Auxilium Pharmaceuticals, Inc. from 2005 to 2015 and Cerulean Pharma, Inc. from 2009 to 2014, and has served on the board of Tecan Group AG since 2011. Dr. Fetzer received a B.S. in Biochemistry from the College of Charleston, his Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an MBA from Carnegie Mellon University.

Mr. Steve Jurvetson is a Managing Director of Draper Fisher Jurvetson (DFJ.com), a leading venture capital firm and one of the most active energy and cleantech investors, with affiliate offices around the world. Steve was the founding VC investor in Hotmail, Interwoven, and Kana. He also led the firm’s investments in Tradex and Cyras (acquired for $8B), and in pioneering companies in synthetic biology and molecular electronics. Previously, Steve was an R&D Engineer at HP, where seven of his communications chip designs were fabricated. His prior technical experience also includes programming, materials science research and computer design at HP, the Center for Materials Research, and Mostek. At Stanford, Steve finished his BSEE in 2.5 years and graduated #1 in his class. He also received an MSEE and MBA from Stanford, and serves as Co-Chair of the NanoBusiness Alliance and President of the Western Association of Venture Capitalists.

Mr. David Kiernan, a graduate of Duke University School of Medicine and Duke University Law School, has an extensive scientific and medical background. David is currently a litigation partner at Williams & Connolly in Washington, DC where his practice area of expertise encompasses commercial, intellectual property (patents and trade secrets), and products liability. His clients have included major pharmaceutical and biotechnology companies.

Mr. Alfonso Romo is the Chairman and Chief Executive Officer of Plenus, S.A. de C.V., and his expertise comes from a long and highly successful business career. Alfonso has been an active investor in many different industries worldwide, where by his leadership these companies consolidated their leading position in such industries as: Consumer Products, Insurance and Financial Services, Packaging, Seeds and Agribusinesses. Currently his investment sectors cover: Education for Profit, Financial Services, Biosciences, Molded Packaging and Infrastructure and Real Estate. In order to support social development, Alfonso has led and implemented innovative programs that contributed to the social and economic development of the agricultural sector; he also supported various educational, cultural and environmental programs. He is a member of the Board of the Donald Danforth Plant Science Center, Cementos Mexicanos, and Gruma.

Martine Rothblatt, Ph.D, MBA, J.D., is a communications technologist and medical biotechnology executive. She founded United Therapeutics in 1996 to address unmet medical needs in pulmonary disease and she currently serves as Chairman and Chief Executive Officer. Prior to United Therapeutics, Dr. Rothblatt created the satellite radio industry and started the satellite communication company SiriusXM. She is a member of the Committee on Science, Technology, and Law of the National Academy of Sciences. Dr. Rothblatt graduated from UCLA with a combined law and MBA degree in 1981 and received her Ph.D. in Medical Ethics in 2001 from University of London.

Mr. Barry Schuler is Chairman and Co-founder of Raydiance, Inc., a DFJ Growth Fund portfolio company. Barry was formerly Chairman/CEO of America Online Inc. and is considered one of the pioneers of the Internet. He has made many notable contributions to the IT industry including developing early video games in the 1970s, pioneering the color desktop presentation category, co-developing the first commercial interactive ecommerce technology which included wallet-based 1-click checkout, co-developing the predecessor to interactive CRM technology developing the first version of America Online designed to appeal to mass market consumers, and notably a member and ultimately leader of the senior management team that matured AOL from $400M to $350B in market cap during 20 consecutive quarters of growth. In addition to SGI, Barry serves on the board of Hands-On Mobile, Inc., UBmatrix, Inc., Visto Corporation, and Raydiance, Inc. He graduated with a B.A. from Rutgers University.

Dr. Hamilton Smith is Co-Chief Scientific Officer at SGI and Scientific Director of the Synthetic Biology team at the J. Craig Venter Institute. Hamilton received the 1978 Nobel Prize for his work on the discovery of restriction enzymes, which are essential tools used in the field of recombinant DNA technology. He is widely considered one of the experts in DNA library construction and DNA manipulation techniques. Hamilton was formerly the senior director of DNA Resources at Celera Genomics. Prior to joining Celera, he joined the scientific team at The Institute for Genomic Research, a position he held after leaving the Johns Hopkins University where he was professor of molecular biology and genetics. He is a member of the National Academy of Sciences.

Mr. (Tan Sri) Lim Kok Thay is the Chairman, President and Chief Executive of the Genting Group, one of Asia’s leading multinational corporations. Tan Sri Lim is instrumental in the internationalization of the Genting Group and was the key driver behind the development of the Group’s casino projects worldwide. Tan Sri Lims visionary foresight and entrepreneurial skills resulted in the birth of Genting Hong Kong Limited which has grown to be the third largest cruise line in the world and the leading cruise operator in Asia-Pacific. Tan Sri Lim guided the Genting Group to expand into other growth areas such as the power generation, plantation, property development, paper and paper-related manufacturing and oil & gas activities. For his invaluable contributions to Malaysia, he was bestowed the highly prestigious national award that carries the titleship of “Tan Sri” by His Majesty, the Yang DiPertuan Agong of Malaysia in June 2002. Tan Sri Lim also serves as the Joint Chief Executive of Asiatic Development Berhad, the plantation and property arm of the Genting Group and the Executive Chairman of Genting International P.L.C. In addition, he sits on the boards of other Malaysian and foreign companies, as well as on the Board of trustees of several charitable organizations in Malaysia.

Dr. J. Craig Venter is regarded as one of the leading scientists of the 21st century for his invaluable contributions in genomic research, most notably for the first sequencing and analysis of the human genome published in 2001 and the most recent and most complete sequencing of his diploid human genome in 2007. Dr. Venter provides visionary guidance and strategic scientific direction for the company. Craig is also Co-founder, CEO and Executive Chairman of Human Longevity Inc. (HLI) and CEO and Chairman of the not-for-profit J. Craig Venter Institute. He and his teams have sequenced more than 300 organisms including human, fruit fly, mouse, rat, and dog as well as numerous microorganisms and plants. Craig is also the key leader in the field of synthetic genomics. He and his team at JCVI constructed the first synthetic bacterial cell, work that is leading to extraordinary advances in engineering microorganisms for many vital applications used at SGI.

Craig is the author of more than 200 research articles and is among the most cited scientists in the world. He is the recipient of numerous honorary degrees and scientific awards including the 2008 National Medal of Science. Craig is also a member of many prestigious scientific organizations including the National Academy of Sciences.